000650 仁和药业
已收盘 08-28 15:00:00
资讯
新帖
简况
仁和药业（000650）2026年中报简析：营收净利润同比双双增长
证券之星 · 08-27 06:22
仁和药业（000650）2026年中报简析：营收净利润同比双双增长
仁和药业：公司销售的产品都是公司的产品
证券之星 · 08-26
仁和药业：公司销售的产品都是公司的产品
图解仁和药业中报：第二季度单季净利润同比增长20.18%
证券之星 · 08-26
图解仁和药业中报：第二季度单季净利润同比增长20.18%
公司问答丨仁和药业：公司自有产品有很多 如仁和可立克、仁和优卡丹、闪亮滴眼露、妇炎洁系列等
格隆汇 · 08-24
公司问答丨仁和药业：公司自有产品有很多 如仁和可立克、仁和优卡丹、闪亮滴眼露、妇炎洁系列等
公司问答丨仁和药业：仁和氧氟沙星胶囊等是公司生产和销售的抗生素类产品
格隆汇 · 08-24
公司问答丨仁和药业：仁和氧氟沙星胶囊等是公司生产和销售的抗生素类产品
股市必读：仁和药业(000650)股东户数9.03万户，较上期增加1.92%
证券之星 · 08-24
股市必读：仁和药业(000650)股东户数9.03万户，较上期增加1.92%
仁和药业：截至2026年8月20日，大约9.03万户左右
证券之星 · 08-21
仁和药业：截至2026年8月20日，大约9.03万户左右
仁和药业：与西部证券达成全面战略合作协议
证券之星 · 08-20
仁和药业：与西部证券达成全面战略合作协议
仁和药业：强化巩固“中药+化药+大健康”业务布局
证券之星 · 08-19
仁和药业：强化巩固“中药+化药+大健康”业务布局
股市必读：仁和药业（000650）8月18日董秘有最新回复
证券之星 · 08-19
股市必读：仁和药业（000650）8月18日董秘有最新回复
公司问答丨仁和药业：ULOOK眼镜处于销售测试和改进阶段 技术成熟稳定后即可量产
格隆汇 · 08-18
公司问答丨仁和药业：ULOOK眼镜处于销售测试和改进阶段 技术成熟稳定后即可量产
仁和药业：已获得清肺汤颗粒药品批文
证券之星 · 08-18
仁和药业：已获得清肺汤颗粒药品批文
仁和药业：2025年8月21日在香港新设成立仁和国际投资控股（香港）有限公司
证券之星 · 08-18
仁和药业：2025年8月21日在香港新设成立仁和国际投资控股（香港）有限公司
股市必读：仁和药业（000650）8月14日董秘有最新回复
证券之星 · 08-17
股市必读：仁和药业（000650）8月14日董秘有最新回复
仁和药业：RM301B滴眼液产品，属于化药2.2类改良型新药
证券之星 · 08-14
仁和药业：RM301B滴眼液产品，属于化药2.2类改良型新药
股市必读：仁和药业（000650）8月13日董秘有最新回复
证券之星 · 08-14
股市必读：仁和药业（000650）8月13日董秘有最新回复
仁和药业：公司主营药品、大健康产品的生产和销售
证券之星 · 08-13
仁和药业：公司主营药品、大健康产品的生产和销售
股市必读：仁和药业(000650)股东户数8.86万户，较上期增加0.45%
证券之星 · 08-12
股市必读：仁和药业(000650)股东户数8.86万户，较上期增加0.45%
仁和药业：截至2026年8月10日，大约8.86万户左右
证券之星 · 08-11
仁和药业：截至2026年8月10日，大约8.86万户左右
股市必读：仁和药业新发布《关于回购公司股份实施结果暨股份变动的公告》
证券之星 · 08-10
股市必读：仁和药业新发布《关于回购公司股份实施结果暨股份变动的公告》
加载更多
公司概况
公司名称：
仁和药业股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-10
主营业务：
仁和药业股份有限公司的主营业务是药品及大健康产品的生产和销售。公司的主要产品是药品、健康相关产品。
发行价格：
6.26
{"stockData":{"symbol":"000650","market":"SZ","secType":"STK","nameCN":"仁和药业","latestPrice":5.57,"timestamp":1787900604000,"preClose":5.54,"halted":0,"volume":23918224,"delay":0,"changeRate":0.0054,"floatShares":1331000000,"shares":1400000000,"eps":0.282,"marketStatus":"已收盘","change":0.03,"latestTime":"08-28 15:00:00","open":5.53,"high":5.58,"low":5.46,"amount":132000000,"amplitude":0.0217,"askPrice":5.58,"askSize":3145,"bidPrice":5.57,"bidSize":1658,"shortable":0,"etf":0,"ttmEps":0.282,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":5,"adr":0,"adjPreClose":5.54,"symbolType":"stock","openAndCloseTimeList":[[1787880600000,1787887800000],[1787893200000,1787900400000]],"highLimit":6.09,"lowLimit":4.99,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1399938234,"isCdr":false,"pbRate":1.19,"roa":"--","peRate":19.751773,"roe":"4.52%","epsLYR":0.28,"committee":-0.528204,"marketValue":7798000000,"turnoverRate":0.018,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-08-31。","floatMarketCap":7416000000},"requestUrl":"/m/hq/s/000650","defaultTab":"news","newsList":[{"id":"2662759740","title":"仁和药业（000650）2026年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759740","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662759740?lang=zh_cn&edition=full","pubTime":"2026-08-27 06:22","pubTimestamp":1787782949,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期仁和药业发布2026年中报。根据财报显示，仁和药业营收净利润同比双双增长。截至本报告期末，公司营业总收入20.91亿元，同比上升5.87%，归母净利润2.92亿元，同比上升0.52%。按单季度数据看，第二季度营业总收入9.62亿元，同比下降2.8%，第二季度归母净利润1.52亿元，同比上升20.18%。本文数据来源于仁和药业2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700011532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662763157","title":"仁和药业：公司销售的产品都是公司的产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2662763157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662763157?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:18","pubTimestamp":1787703502,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)08月25日在投资者关系平台上答复投资者关心的问题。投资者提问：公司所出售的所有非处方药产品，全部是贴牌产品还是有很少部分是公司自己研发生产的自有产品？谢谢！仁和药业回复：尊敬的投资者，谢谢您的关注！公司销售的产品都是公司的产品，无论是自有生产还是OEM代工生产，公司始终把产品质量放在首位。自有产品是根本，OEM是有益补充。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600014102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0097","BK0239","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662751776","title":"图解仁和药业中报：第二季度单季净利润同比增长20.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662751776","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662751776?lang=zh_cn&edition=full","pubTime":"2026-08-26 03:14","pubTimestamp":1787685281,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业2026年中报显示，上半年度公司主营收入20.91亿元，同比上升5.87%；归母净利润2.92亿元，同比上升0.52%；扣非净利润2.53亿元，同比上升22.43%；其中2026年第二季度，公司单季度主营收入9.62亿元，同比下降2.8%；单季度归母净利润1.52亿元，同比上升20.18%；单季度扣非净利润1.17亿元，同比上升11.95%；负债率11.85%，投资收益1533.07万元，财务费用52.42万元，毛利率35.96%。财报数据概要请见下图:本文数据来源于仁和药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600005496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661240882","title":"公司问答丨仁和药业：公司自有产品有很多 如仁和可立克、仁和优卡丹、闪亮滴眼露、妇炎洁系列等","url":"https://stock-news.laohu8.com/highlight/detail?id=2661240882","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661240882?lang=zh_cn&edition=full","pubTime":"2026-08-24 17:15","pubTimestamp":1787562956,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0214","002782","BK0239","BK0188","000650","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661229216","title":"公司问答丨仁和药业：仁和氧氟沙星胶囊等是公司生产和销售的抗生素类产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2661229216","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661229216?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:01","pubTimestamp":1787558494,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","BK0097","BK0188","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661024558","title":"股市必读：仁和药业(000650)股东户数9.03万户，较上期增加1.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661024558","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661024558?lang=zh_cn&edition=full","pubTime":"2026-08-24 02:18","pubTimestamp":1787509093,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，仁和药业报收于5.37元，下跌4.45%，换手率3.08%，成交量40.98万手，成交额2.22亿元。股本股东变化：截至2026年8月20日，仁和药业股东户数为9.03万户，较8月10日增长1.92%，户均持股数量降至1.55万股。敬请发布截至昨天8月20日公司的股东户数信息，谢谢！董秘： 谢谢您的关注，截至2026年8月20日，大约9.03万户左右。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400001135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0188","BK0097","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661250196","title":"仁和药业：截至2026年8月20日，大约9.03万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2661250196","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661250196?lang=zh_cn&edition=full","pubTime":"2026-08-21 15:06","pubTimestamp":1787295987,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)08月21日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘 你好 衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2026年8月20日A股股东人数是多少？谢谢仁和药业回复：谢谢您的关注，截至2026年8月20日，大约9.03万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100021985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","BK0188","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660699282","title":"仁和药业：与西部证券达成全面战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2660699282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660699282?lang=zh_cn&edition=full","pubTime":"2026-08-20 20:51","pubTimestamp":1787230267,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)08月19日在投资者关系平台上答复投资者关心的问题。投资者提问：三个月前，仁和药业和西部证券达成战略合作。公司是医药企业，西部证券是金融企业，两家公司合作的范围有哪些？对公司带来哪些益处？仁和药业回复：尊敬的投资者，去年公司与西部证券达成全面战略合作协议，根据协议，仁和药业与西部证券将充分发挥各自在产业资源、资本运作、金融服务及市场拓展等方面的核心优势，建立长期、稳定、互惠的战略合作关系。详细情况请您查阅公司官网相关内容。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000041878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","000650","BK0028","BK0276","BK0097","002673","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660458354","title":"仁和药业：强化巩固“中药+化药+大健康”业务布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2660458354","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660458354?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:27","pubTimestamp":1787128026,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)08月19日在投资者关系平台上答复投资者关心的问题。投资者提问：根据公司新闻，公司荣获“2026中国中成药企业综合竞争力50强”。请问：公司获得该榜单的核心竞争力有哪些？谢谢仁和药业回复：尊敬的投资者，您好！既是荣誉也是证明。仁和药业地处中国药都樟树市，公司强化巩固“中药+化药+大健康”业务布局，加大中药研发、生产、品牌投入，持续推进古代经典名方、中药智能制造的战略定位，这也符合国家中医药振兴政策方向。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900027991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","000650","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660499729","title":"股市必读：仁和药业（000650）8月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660499729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660499729?lang=zh_cn&edition=full","pubTime":"2026-08-19 02:02","pubTimestamp":1787076140,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，仁和药业报收于5.46元，下跌0.18%，换手率1.42%，成交量18.97万手，成交额1.04亿元。董秘最新回复投资者： 近期，创新药股票如哈药股份、百花医药等股票走势均翻倍。公司于2025年8月21日在香港新设成立仁和国际投资控股（香港）有限公司，2025年报全文里有披露。公司2026年第一季度报告显示，公司一季度归母净利1.4亿元，扣非净利1.36亿元，扣非同比增长33.20%，说明公司主营业绩有较好的增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0097","BK0239","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660468660","title":"公司问答丨仁和药业：ULOOK眼镜处于销售测试和改进阶段 技术成熟稳定后即可量产","url":"https://stock-news.laohu8.com/highlight/detail?id=2660468660","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660468660?lang=zh_cn&edition=full","pubTime":"2026-08-18 16:25","pubTimestamp":1787041547,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0188","BK0239","000650","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660345942","title":"仁和药业：已获得清肺汤颗粒药品批文","url":"https://stock-news.laohu8.com/highlight/detail?id=2660345942","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660345942?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:33","pubTimestamp":1787024000,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业08月18日在投资者关系平台上答复投资者关心的问题。中药创新以古代中药经典名方为主，今年6月，公司获得了中药3.1类古代经典名方中药复方制剂清肺汤颗粒的药品批文。公司已获得二冬汤颗粒、清肺汤颗粒药品批件，在研的还有温经汤、泻白散等十余款经典名方。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800016057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000650","BK0239","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660459475","title":"仁和药业：2025年8月21日在香港新设成立仁和国际投资控股（香港）有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2660459475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660459475?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:33","pubTimestamp":1787023996,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)08月18日在投资者关系平台上答复投资者关心的问题。投资者提问：公司产品是否有海外布局的计划？仁和药业回复：尊敬的投资者，您好！公司于2025年8月21日在香港新设成立仁和国际投资控股（香港）有限公司，2025年报全文里有披露。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800016053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0097","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660702881","title":"股市必读：仁和药业（000650）8月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660702881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660702881?lang=zh_cn&edition=full","pubTime":"2026-08-17 02:32","pubTimestamp":1786905131,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，仁和药业报收于5.46元，下跌0.73%，换手率1.61%，成交量21.38万手，成交额1.17亿元。公司药品自有研发主要是仿制药、一致性评价、中药经典名方，已获批：磷酸奥司他韦胶囊/干混悬剂、玻璃酸钠滴眼液、西地那非、他达拉非等。公司已获得二冬汤颗粒、清肺汤颗粒药品批件，在研的还有温经汤、泻白散等十余款经典名方。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700000937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","000650","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659191201","title":"仁和药业：RM301B滴眼液产品，属于化药2.2类改良型新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2659191201","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659191201?lang=zh_cn&edition=full","pubTime":"2026-08-14 15:42","pubTimestamp":1786693339,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业08月14日在投资者关系平台上答复投资者关心的问题。投资者提问：眼部创新药RM301B目前进展程度如何，属于全球首创么？RM301B滴眼液产品，属于化药2.2类改良型新药，适应症为视网膜静脉阻塞性黄斑水肿。公司药品自有研发主要是仿制药、一致性评价、中药经典名方，已获批：磷酸奥司他韦胶囊/干混悬剂、玻璃酸钠滴眼液、西地那非、他达拉非等。在研以仿制药改良、剂型改良为主。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400021317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000650","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659616198","title":"股市必读：仁和药业（000650）8月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2659616198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659616198?lang=zh_cn&edition=full","pubTime":"2026-08-14 02:08","pubTimestamp":1786644496,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，仁和药业报收于5.5元，上涨0.92%，换手率2.54%，成交量33.8万手，成交额1.86亿元。董秘最新回复投资者： 请问公司在创新药方面是否有布局？建议您查阅公司2025年度报告全文第三节，特别是研发投入部分和公司未来发展部分。公司主营药品、大健康产品的生产和销售。当日关注点交易信息汇总：8月13日主力资金净流出228.87万元，占总成交额1.23%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","000650","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659713281","title":"仁和药业：公司主营药品、大健康产品的生产和销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2659713281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659713281?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:12","pubTimestamp":1786608732,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)08月13日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在脑机接口方面是否有布局？仁和药业回复：尊敬的投资者，您好！公司主营药品、大健康产品的生产和销售。未来公司发展，建议您查阅公司2025年度报告全文版之公司未来发展的展望章节。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300024710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","000650","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658066912","title":"股市必读：仁和药业(000650)股东户数8.86万户，较上期增加0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658066912","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658066912?lang=zh_cn&edition=full","pubTime":"2026-08-12 01:42","pubTimestamp":1786470132,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，仁和药业报收于5.42元，下跌0.37%，换手率1.28%，成交量16.99万手，成交额9292.93万元。股本股东变化股东户数变动截至2026年8月10日，仁和药业股东户数为8.86万户，较7月31日增加400户，增幅0.45%；户均持股数量由1.59万股减少至1.58万股，户均持股市值为8.6万元。敬请发布截至今天收盘公司8月上旬末的股东户数信息。董秘： 谢谢您的关注，截至2026年8月10日，大约8.86万户左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200001859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","BK0188","000650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658693769","title":"仁和药业：截至2026年8月10日，大约8.86万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2658693769","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658693769?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:33","pubTimestamp":1786419186,"startTime":"0","endTime":"0","summary":"证券之星消息，仁和药业(000650)08月11日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘 你好 衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2026年8月10日A股股东人数是多少？谢谢仁和药业回复：谢谢您的关注，截至2026年8月10日，大约8.86万户左右。具体数据，根据相关法规，请您先向公司证券部提交股东身份证明，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100014666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","000650","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670463","title":"股市必读：仁和药业新发布《关于回购公司股份实施结果暨股份变动的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670463","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658670463?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:24","pubTimestamp":1786296251,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，仁和药业报收于5.43元，上涨1.88%，换手率1.68%，成交量22.35万手，成交额1.2亿元。公司公告汇总：仁和药业完成股份回购，累计回购17,700,050股，成交金额99,999,600.10元，回购价格区间为4.86元/股至5.73元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","000650","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787993772826,"stockEarnings":[{"period":"1week","weight":0.0372},{"period":"1month","weight":0.0183},{"period":"3month","weight":0.0695},{"period":"6month","weight":-0.0497},{"period":"1year","weight":-0.0831},{"period":"ytd","weight":0.0127}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.0323},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0283},{"period":"ytd","weight":-0.0042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"仁和药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"90300人(较上一季度增加1.92%)","perCapita":"14744股","listingDate":"1996-12-10","address":"江西省宜春市樟树市葛玄路6号","registeredCapital":"139993万元","survey":" 仁和药业股份有限公司的主营业务是药品及大健康产品的生产和销售。公司的主要产品是药品、健康相关产品。","listedPrice":6.26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仁和药业,000650,仁和药业股票,仁和药业股票老虎,仁和药业股票老虎国际,仁和药业行情,仁和药业股票行情,仁和药业股价,仁和药业股市,仁和药业股票价格,仁和药业股票交易,仁和药业股票购买,仁和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}